Autopsy report · NCT01712815

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

“Insufficient accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 8 years 11 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

University of Southern California

Sponsor type

University, hospital or other

Conditions

HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer

Interventions

laboratory biomarker analysis; pharmacological study; questionnaire administration; fluorine F 18-clevudine; positron emission tomography/computed tomography

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
  “failure to accrue” (89% match in meaning)
• Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
  “Insufficient accrual rate” (85% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (84% match in meaning)
• Osteoarthritis Shoulder Injection Study
  “insufficient rate of accrual” (83% match in meaning)
• A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
  “unable to accrue” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.